To investigate whether blocking the IRE1/XBP1 pathway is a therapeutic for MM, researchers performed chemical library screening and they identified a small-molecule, STF-083010, that specifically blocks the endonuclease activity of IRE1 without affecting its kinase activity (Papandreou et al., 2011). Here, XBP1 is linked to Miyoshi myopathy.